Published online Jun 15, 2013. doi: 10.4239/wjd.v4.i3.82
Revised: April 21, 2013
Accepted: May 9, 2013
Published online: June 15, 2013
Processing time: 164 Days and 22.4 Hours
AIM: To determine the frequency of atherosclerotic cardiovascular disease and its risk factors among patients with type 2 diabetes in Basrah, Iraq.
METHODS: Participants in this cross-sectional study were patients who had type 2 diabetes for at least 1 year, presenting at the Al-Faiha Diabetes Endocrine and Metabolism Center in Basrah (Southern Iraq) over the period from January to December 2008.
RESULTS: The series included 1079 patients (58.8% men), of whom 25.0% were smokers. The prevalence of symptomatic cardiovascular disease and hypertension was 16.0%, and 44.3% respectively. Those who were overweight or obese constituted 70.5%. Insulin was used in only 26.9% despite 56.1% having had diabetes for 6 years and more. The mean glycated hemoglobin (HbA1c) was 9.46% ± 2.0% and only 5.5% achieved the target of HbA1c of < 7%. We had 68.7% of patients with total cholesterol of ≥ 200 mg/dL, 21.5% with high density lipoprotein cholesterol of < 40 mg/dL, 84.1% with low density lipoprotein cholesterol of ≥ 100 mg/dL and 71.6% with triglyceride of ≥ 150 mg/dL.
CONCLUSION: Among adults with type 2 diabetes mellitus, there was increased frequency of cardiovascular disease and its modifiable risk factors. This finding necessitated urgent work to modify these risk factors in a population based setting.
Core tip: Atherosclerotic cardiovascular complications are mainly responsible for the high morbidity and mortality in people with diabetes. We studied 1079 patients with type 2 diabetes mellitus to determine the frequency of atherosclerotic cardiovascular disease and its risk factors. The main finding of this study was an increased frequency of cardiovascular disease and its modifiable risk factors among patients with type 2 diabetes in Basrah, Iraq.
- Citation: Mansour AA, Ajeel NA. Atherosclerotic cardiovascular disease among patients with type 2 diabetes in Basrah. World J Diabetes 2013; 4(3): 82-87
- URL: https://www.wjgnet.com/1948-9358/full/v4/i3/82.htm
- DOI: https://dx.doi.org/10.4239/wjd.v4.i3.82
In 2004, the World Health Organization projected that by 2030, the global prevalence of diabetes would double, to affect an estimated 366 million individuals, representing 4.4% of the world population[1].
Atherosclerotic cardiovascular complications are mainly responsible for the high morbidity and mortality in people with diabetes[2-4]. Cardiovascular disease (CVD), which includes coronary heart disease (CHD), and stroke, accounts for up to 80% of all deaths among patients with diabetes[5], compared with one-third of all deaths in the general population[6]. This CVD rate in people with type 2 diabetes also varies according to ethnicity[7].
Atherosclerosis in diabetes is more precocious, aggressive and multi-focal than in the non-diabetic population[8]. That is why it is recommended to decrease low density lipoprotein cholesterol (LDL-C) < 100 mg/dL (< 70 mg/dL in people with overt CHD with diabetes)[9]. From a cardiovascular point of view, it has been suggested that diabetic patients should be considered as about 15 years older than the general population[10]. The chance of cardiovascular events in diabetic patients is as high as in patients with a previous history of myocardial infarction but without diabetes[11]. Risk factors for CVD in people with diabetes include age, duration of diabetes, smoking, abnormal lipid profiles, raised blood pressure and albuminuria[12,13].
The aim of this study was to determine the frequency of atherosclerotic CVD and its risk factors among patients with type 2 diabetes in Basrah, Iraq.
Participants in this cross-sectional study were patients who had type 2 diabetes for at least 1 year, presenting at the Al-Faiha Diabetes, Endocrine and Metabolism Center in Basrah (Southern Iraq) over the period from January to December 2008 and who had not received lipid lowering agents prior to enrollment. This center received patients from all over Basrah and it is the only qualified center treating diabetes in Southern Iraq. Participants gave written consents and the ethical committee of Basrah College of Medicine approved the study.
The definition of CVD included CHD and cerebrovascular accidents(CVA; stroke). CHD diagnosis was based on a history of admission to CCU with elevated cardiac biomarkers, electrocardiographic evidence of ST elevation, Q wave myocardial infarction or left bundle branch block, echocardiographic segmental wall motion abnormalities, abnormal angio-cardiography, percutaneous coronary intervention or coronary artery bypass surgery. The CVA was diagnosed on the basis of sudden neurological deficit that lasted for 24 h, with or without neuroimaging changes.
Potential risk factors for CVD included age, gender, smoking status, waist circumference (WC), body mass index (BMI), hypertension, duration of diabetes, glycated hemoglobin (HbA1c), insulin use, serum total cholesterol and high density lipoprotein cholesterol (HDL-C), triglycerides (TG), and LDL-C. Current smoker was defined as any person who had smoked cigarettes in the preceding three months, regardless of the number.
Hypertension was defined as systolic blood pressure of 140 mmHg or higher, diastolic blood pressure of 90 mmHg or higher, use of antihypertensive agents or a combination of these. Blood pressure was measured in a seated position after 5 min at rest, three times. The average of the second and third readings was defined as the subject’s blood pressure.
Diabetes mellitus was defined as plasma glucose level being 200 mg/dL or higher independent of fasting time, fasting plasma glucose of ≥ 126 mg/dL on two occasions, use of anti-diabetes agents or a combination of these[14]. After failure of oral antihyperglycemic agents failed we started with basal human insulin neutral protamine Hagedorn at bedtime then basal prandial or premixed twice.
The waist circumference, was measured in centimeters using a plastic anthropometric tape from the horizontal plane at the umbilical level. Measurement was made with the participant standing erect, abdomen relaxed, arms at the side and feet together with weight equally divided over both legs. Participants were told to breathe normally and to breathe out gently at the time of measurement and not to hold in their abdomen or hold their breath. BMI was calculated as body weight in kilograms divided by the squared value of body height in meters (kg/m2).
Fasting serum samples were analyzed in the same local laboratory. Blood (10 mL) was drawn into a tube after the subject had fasted for at least 10 h. Serum total cholesterol, HDL-C, and TG were measured by the enzymatic method. LDL-C concentrations were calculated using the Friedewald formula. Risk factors in the lipoprotein profile of participants would be a total cholesterol of equal or more than 200 mg/dL, LDL-C equal or more than 100 mg/dL, HDL-C less than 40 mg/dL and TG level equal or more than 150 mg/dL[14,15]. HbA1c was measured using a fully automated glycohemoglobin analyzer which uses high performance liquid chromatography.
Data analysis was performed using the Statistical Package for Social Sciences (SPSS) version 15 (SPSS Inc, Chicago, Illinois, United States). Characteristics of the sample are reported as mean ± SD or frequencies and percentages. Pearson’s χ2 was used to examine if there is an association between two categorical variables and Student’s t test were used for continuous variables.
Table 1 shows the basic socio-demographic and cardiovascular risk factors. The series included 1079 patients (58.8% men, mean age 56.3 ± 11.37 years; age range, 26-94 years) with a mean qualification period of 6.0 ± 6.0 years and 25.0% were current smokers. The mean duration of type 2 diabetes was of 7.4 ± 6.5 years.
Variable | ||
Sex | Men | 634 (58.8) |
Women | 445 (41.2) | |
Age (yr) | mean ± SD | 56.3 ± 11.37 |
< 40 | 83 (7.7) | |
40–49 | 220 (20.4) | |
50–59 | 330 (30.6) | |
≥ 60 | 41.3 (41.3) | |
Education (yr) | mean ± SD | 6.0 ± 6.0 |
Illiterate | 455 (42.2) | |
≤ 9 | 326 (30.2) | |
≥ 10 | 298 (27.6) | |
Current smoking | Yes | 270 (25.0) |
No | 809 (75.0) | |
Duration of diabetes (yr) | mean ± SD | 7.4 ± 6.5 |
≤ 5 | 474 (43.9) | |
6-10 | 361 (33.5) | |
> 10 | 244 (22.6) | |
Known cardiovascular disease | Yes | 173 (16.0) |
No | 906 (83.9) | |
Hypertension | Yes | 478 (44.3) |
No | 601 (55.7) | |
WC (cm) | mean ± SD | 100.2 ± 12.3 |
BMI | mean ± SD | 28.0 ± 5.4 |
< 25 | 318 (29.5) | |
25-29 | 396 (36.7) | |
≥ 30 | 365 (33.8) | |
Insulin use | Yes | 290 (26.9) |
No | 789 (73.1) | |
HbA1c (% total Hb) | mean ± SD | 9.46 ± 2.0 |
< 7 | 59 (5.5 ) | |
≥ 7 | 1020 (94.5) | |
Total cholesterol (mg/dL) | mean ± SD | 206.8 ± 42.6 |
< 200 | 338 (31.3) | |
≥ 200 | 741 (68.7) | |
HDL cholesterol (mg/dL) | mean ± SD | 46.5 ± 13.0 |
< 40 | 232 (21.5) | |
≥ 40 | 847 (78.5) | |
LDL cholesterol (mg/dL) | mean ± SD | 122.6 ± 35.9 |
< 100 | 172 (15.9) | |
≥ 100 | 907 (84.1) | |
Triglycerides (mg/dL) | mean ± SD | 193.5 ± 98.3 |
< 150 | 306 (28.4) | |
≥ 150 | 773 (71.6) |
The prevalence of symptomatic CVD was 16.0% and hypertension was seen in 44.3%. The mean WC was 100.2 ± 12.3 cm and BMI 28.0 ± 5.4 kg/m2. Those who were overweight or obese constituted 70.5%. Insulin was used in 26.9% despite the fact that 56.1% had diabetes for 6 years and more. The mean HbA1c was 9.46 % ± 2.0% and only 5.5% achieved the target of HbA1c of < 7%. We had 68.7% of patients with total cholesterol of ≥ 200 mg/dL, 21.5 % with HDL-C of < 40 mg/dL, 84.1% with LDL-C of ≥ 100 mg/dL and 71.6 % with TG of ≥ 150 mg/dL.
In Table 2, the sociodemographic and cardiovascular risk factors are shown according to gender. There were no differences between the two groups in the age or duration of diabetes. Qualification levels were statistically higher among men, as was the smoking rate (P < 0.0001). Among the 25% current smokers, 87.8% were men. Established CVD and hypertension levels were higher in men (P < 0.0001 and P = 0.048 respectively). There was no difference in the WC but the BMI was higher among women (P = 0.029). Insulin was used more commonly among women (P < 0.0001), but no differences were seen in the mean HbA1c. No significant differences were seen between the two groups regarding total cholesterol or LDL-C. The HDL-C was higher among women (P = 0.040) while TG was higher among men (P = 0.004). Subgroup analysis of the two groups showed total cholesterol ≥ 200 mg/dL and HDL-C < 40 mg/dL was more common among men (P = 0.003 and P < 0.0001 respectively).
Variable | Men | Women | P value | |
Age (yr) | mean ± SD | 56.6 ± 11.5 | 55.8 ± 11.0 | 0.276 |
< 40 | 44 (53.0) | 39 (47.0) | 0.650 | |
40-49 | 133 (60.5) | 87 (39.5) | ||
50-59 | 191 (57.9) | 139 (42.1) | ||
≥ 60 | 266 (59.6) | 180 (40.4) | ||
Education (yr) | mean ± SD | 8.2 ± 2.8 | 3.0 ± 4.7 | < 0.0001 |
Illiterate | 160 (35.2) | 295 (64.8) | < 0.0001 | |
≤ 9 | 228 (69.9) | 98 (30.1) | ||
≥ 10 | 246 (82.6) | 52 (17.4) | ||
Current smoker | Yes | 237 (87.8) | 33 (12.2) | < 0.0001 |
Duration of diabetes (yr) | mean ± SD | 7.6 ± 6.9 | 7.1101 ± 6.02 | 0.149 |
≤ 5 | 267 (56.3) | 207 (43.7) | 0.314 | |
6-10 | 222 (61.5) | 139 (38.5) | ||
> 10 | 145 (59.4) | 99 (40.6) | ||
Known cardiovascular disease | 125 (72.3) | 48 (27.7) | < 0.0001 | |
Hypertension | 265 (55.4) | 213 (44.6) | 0.048 | |
WC (cm) | mean ± SD | 100.15 ± 12.45 | 100.46 ± 12.16 | 0.681 |
BMI | mean ± SD | 27.7 ± 5.0 | 28.5 ± 5.9 | 0.029 |
< 25 | 190 (59.7) | 128 (40.3) | 0.193 | |
25-29 | 243 (61.4) | 153 (38.6) | ||
≥ 30 | 201 (55.1) | 164 (44.9) | ||
Insulin use | Yes | 129 (44.5) | 161 (55.5) | < 0.0001 |
HbA1c (% total Hb) | mean ± SD | 9.32 ± 2.0 | 9.61 ± 2.05 | 0.100 |
< 7 | 35 (59.3) | 24 (40.7) | 0.928 | |
≥ 7 | 599 (58.7) | 421 (41.3) | ||
Total cholesterol (mg/dL) | mean ± SD | 206.2 ± 42.6 | 207.7 ± 42.6 | 0.658 |
< 200 | 221 (65.4) | 117 (34.6) | 0.003 | |
≥ 200 | 413 (55.7) | 328 (44.3) | ||
HDL cholesterol (mg/dL) | mean ± SD | 45.85 ± 14.58 | 47.76 ± 9.84 | 0.040 |
< 40 | 173 (74.6) | 59 (25.4) | < 0.0001 | |
≥ 40 | 461 (54.4) | 386 (45.6) | ||
LDL cholesterol (mg/dL) | mean ± SD | 122.2 ± 35.5 | 123.2 ± 36.5 | 0.723 |
< 100 | 106 (61.6) | 66 (38.4) | 0.447 | |
≥ 100 | 528 (58.2) | 379 (41.8) | ||
Triglycerides (mg/dL) | mean ± SD | 201.0 ± 107.1 | 181.3 ± 80.60 | 0.004 |
< 150 | 179 (58.5) | 127 (41.5) | 0.913 | |
≥ 150 | 455 (58.9) | 318 (41.1) |
The percentage of patients with hypertension, current smoker status and levels of HbA1c, LDL-C, and HDL-C outside the target levels according to the studied variables are summarized in Table 3. Men were more likely to be current smokers and have HDL-C < 40 mg/dL, whereas women were more likely to be hypertensive. There were no differences in risk factors between age groups. Illiterates were more likely to be hypertensive and have HbA1c > 7%. Those with a duration of diabetes greater than 5 years and those with high BMI and WC ≥ 80 cm were more likely to be hypertensive. Insulin was used less in those who were smokers, and had LDL-C ≥ 100 mg/dL but was used more in those with HbA1c ≥ 7%.
Variable (%) | Current smoking | Blood pressure (≥140/90 mmHg) | HbA1c (≥7%) | LDL cholesterol (≥100 mg/dL) | HDL cholesterol (< 40 mg/dL) |
All | 25.0 | 44.3 | 86.1 | 84.1 | 27.6 |
Gender | |||||
Men | 37.4 | 41.8 | 84.4 | 83.3 | 32.8 |
Women | 7.4 | 47.9 | 87.8 | 85.2 | 18.7 |
P value | < 0.0001 | 0.048 | 0.267 | 0.447 | < 0.0001 |
Age (yr) | |||||
< 40 | 27.7 | 45.8 | 87.2 | 84.3 | 33.9 |
40-49 | 26.8 | 39.5 | 87.3 | 81.4 | 26.2 |
50-59 | 21.2 | 45.5 | 84.4 | 83.9 | 27.4 |
≥ 60 | 26.5 | 45.5 | 86.4 | 85.4 | 27.3 |
P value | 0.291 | 0.469 | 0.905 | 0.610 | 0.727 |
Education (yr) | |||||
Illiterate | 19.3 | 52.3 | 86.6 | 87.9 | 26.1 |
≤ 9 | 31.0 | 35.3 | 90.7 | 82.8 | 27.8 |
≥ 10 | 27.2 | 41.9 | 79.4 | 79.5 | 29.2 |
P value | 0.001 | < 0.0001 | 0.020 | 0.007 | 0.693 |
Duration (yr) | |||||
≤ 5 | 25.3 | 28.7 | 85.4 | 84.6 | 24.6 |
6-10 | 26.3 | 58.4 | 85.2 | 84.8 | 28.5 |
> 10 | 22.3 | 55.8 | 88.6 | 82.0 | 31.7 |
P value | 0.545 | < 0.0001 | 0.672 | 0.596 | 0.207 |
BMI (kg/m2) | |||||
< 25 | 25.8 | 31.1 | 84.0 | 84.9 | 28.4 |
25-29.9 | 23.2 | 47.0 | 84.6 | 81.6 | 26.6 |
≥ 30 | 26.3 | 52.9 | 89.7 | 86.0 | 27.9 |
P value | 0.579 | < 0.0001 | 0.254 | 0.216 | 0.873 |
WC (cm) | |||||
< 80 | 25.9 | 15.5 | 88.6 | 81.0 | 23.7 |
≥ 80 | 25.0 | 45.9 | 85.9 | 84.2 | 27.7 |
P value | 0.879 | < 0.0001 | 0.656 | 0.466 | 0.585 |
Insulin use | |||||
Yes | 18.3 | 40.0 | 92.8 | 79.7 | 26.3 |
No | 27.5 | 45.9 | 80.7 | 85.7 | 28.0 |
P value | 0.002 | 0.085 | < 0.0001 | 0.019 | 0.624 |
The prevalence of symptomatic CVD in our study was 16.0%; Current smokers were 25.0%; Hypertension was seen in 44.3% and 70.5% were overweight or obese. In Kuwait, 59.3% of patients with type 2 diabetes were hypertensive, 26.3% were overweight, 65.0% were obese, history of CVD was present in 10.0% of patients and 13.3% were smokers[16]. Among centers for diabetes, at the University of Jordan, Amman, in patients with type 2 diabetes approximately 70.0% of the patients had hypertension[17].
In a cohort study of diabetic patients in Lebanon, 43.8% patients were obese, 35.0% were current smokers and hypertension was present in 53.2%[18]. Among 1846 patients with diabetes in Spain, obesity and high blood pressure were present in > 50.0%, and established CVD in 24.0%[19]. Of patients with type 2 diabetes in a district of Madrid, Spain, only 13.0% had a BMI < 25 kg/m2[20].
In patients with type 2 diabetes mellitus at primary care settings from the North Catalonia Diabetes Study, CVD prevalence was 22.0%, hypertension 74.5%, smoking 14.9% and obesity 44.9%[21]. Overall, 27.0% of diabetic American Indians reported a history of CVD and 57.0% had hypertension[22]. Zhang et al[23] found that in 3469 type 2 diabetic in-patients in China hypertension was seen in 41.8%, CHD in 25.1%, cerebral vascular disease in 17.3%.
In our study the mean HbA1c was 9.46% ± 2.0% and only 5.5% achieved the target HbA1c of < 7% while in Kuwait it was 16.2%[16], in Spain 41%[20], in Germany 46.6%[24] and in Lebanon, 32% of patients with type 2 diabetes had HbA1c of ≤ 7%[18]. The association between HbA1c and CVD in type 2 diabetes is well known with a relative risk of 1.18 (95%CI: 1.10-1.26) for CVD with a 1% increase in HbA1c[25].
The insulin was used in our study by 26.9 % of patients despite the fact that 56.1 % had diabetes for 6 years and more. In Lebanon, only 20.0% of patients were taking insulin[18].
In this study, majority of our patients had lipid profiles outside of the target range. In one study on lipid profile in apparently healthy volunteers in Mosul, Iraq, 42% of the study population had TG > 150 mg/dL, 58% had LDL-C > 100 mg/dL, and 50 % had HDL-C < 40 mg/dL[26]. There was no difference in the prevalence of elevated LDL-C by the studied variables except for less use of insulin, a finding that was also seen in Kuwaiti patients[16]. In Kuwait, 86.2% overall and 63.2% of the patients with type 2 diabetes had LDL-C > 100 mg/dL and HDL-C outside the target levels[16]. The North Catalonia Diabetes Study showed dyslipidemia in 77.7%[21]. In Jordan, patients with type 2 diabetes had high LDL-C (≥ 100 mg/dL) in 91.5%, low HDL-C in 83.9%, high TG in 83.1% and high total cholesterol in 77.2%[17]. In Augsburg Diabetes Family Study, total cholesterol was seen as < 200 mg/dL in 44.1%, and LDL-C was < 100 mg/dL in 16.0% of the participants[24].
In this study the smoking rate among men was higher than in other studies. Established CVD and hypertension were found more in men, while BMI was higher among women. In Kuwait, hypertension was more prevalent among women than men and smoking was only present among men[16]. The BMI, and HDL-C were significantly higher in women than men, while TG and total cholesterol was higher among men in Kuwait.
In conclusion, our study demonstrated that among adults with type 2 diabetes mellitus, there was increased frequency of cardiovascular disease and its modifiable risk factors. This finding suggests a need for urgent work to modify these risk factors in the population-based setting.
The author wish to thank Lesley Pocock, Publisher and Managing Director medi+WORLD International World CME for reviewing of the manuscript. The efforts made by the medical staff of the Al-Faiha Diabetes, Endocrine and Metabolism Center in Basrah throughout the study were highly appreciated.
Atherosclerotic cardiovascular complications are mainly responsible for the high morbidity and mortality in people with diabetes. Cardiovascular disease (CVD), which includes coronary heart disease, and stroke, accounts for up to 80% of all deaths among patients with diabetes, compared with one-third of all deaths in the general population. The CVD rate in people with type 2 diabetes also varies according to ethnicity.
The prevalence of symptomatic CVD was 16.0% and hypertension was seen in 44.3% of patients. Those who were overweight or obese constituted 70.5%. Only 5.5% achieved the target of hypertension, duration of diabetes, and glycated hemoglobin (HbA1c) of < 7%. The authors found 68.7% of patients with total cholesterol of ≥ 200 mg/dL, 21.5% with high density lipoprotein cholesterol (HDL-C) of < 40 mg/dL, 84.1% with low density lipoprotein cholesterol (LDL-C) of ≥ 100 mg/dL and 71.6 % with triglycerides (TG) of ≥ 150 mg/dL.
Potential risk factors for CVD included age, gender, smoking status, waist circumference, body mass index, hypertension, duration of diabetes, HbA1c, insulin use, serum total cholesterol and HDL-C, TG and LDL-C. This study demonstrated that among adults with type 2 diabetes mellitus, there was increased frequency of cardiovascular disease and its modifiable risk factors.
This finding suggests a need for urgent work to modify these risk factors in the population-based setting.
Well written study report provides epidemiological data from a cohort of type 2 diabetes patients in Iraq.
P- Reviewers Mimeault M, Ndisang J, Zdravkovic M S- Editor Huang XZ L- Editor Hughes D E- Editor Li JY
1. | Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9344] [Cited by in F6Publishing: 8808] [Article Influence: 440.4] [Reference Citation Analysis (1)] |
2. | Fagan TC, Sowers J. Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy. Arch Intern Med. 1999;159:1033-1034. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
3. | Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747-1759. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 418] [Cited by in F6Publishing: 429] [Article Influence: 21.5] [Reference Citation Analysis (0)] |
4. | Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4846] [Cited by in F6Publishing: 4412] [Article Influence: 169.7] [Reference Citation Analysis (1)] |
5. | Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38:46-51. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 758] [Cited by in F6Publishing: 679] [Article Influence: 14.1] [Reference Citation Analysis (0)] |
6. | Shen WF. Screening for coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. Zhonghua Yixve Zazhi. 2007;120:1859-1861. [PubMed] [Cited in This Article: ] |
7. | Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32). Diabetes Care. 1998;21:1271-1277. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 72] [Cited by in F6Publishing: 78] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
8. | Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527-1532. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 883] [Cited by in F6Publishing: 899] [Article Influence: 42.8] [Reference Citation Analysis (0)] |
9. | American Diabetes Association. Standards of medical care in diabetes--2006. Diabetes Care. 2006;29 Suppl 1:S4-42. [PubMed] [Cited in This Article: ] |
10. | Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368:29-36. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 498] [Cited by in F6Publishing: 478] [Article Influence: 26.6] [Reference Citation Analysis (0)] |
11. | Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117:1945-1954. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 377] [Cited by in F6Publishing: 389] [Article Influence: 24.3] [Reference Citation Analysis (0)] |
12. | Davis TM, Millns H, Stratton IM, Holman RR, Turner RC. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med. 1999;159:1097-1103. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 143] [Cited by in F6Publishing: 135] [Article Influence: 5.4] [Reference Citation Analysis (0)] |
13. | Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828. [PubMed] [Cited in This Article: ] |
14. | American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28 Suppl 1:S37-S42. [PubMed] [Cited in This Article: ] |
15. | National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421. [PubMed] [Cited in This Article: ] |
16. | Al-Adsani AM. Cardiovascular risk factors in Kuwaiti adults with type 2 diabetes. Saudi Med J. 2008;29:1669-1671. [PubMed] [Cited in This Article: ] |
17. | Abdel-Aal NM, Ahmad AT, Froelicher ES, Batieha AM, Hamza MM, Ajlouni KM. Prevalence of dyslipidemia in patients with type 2 diabetes in Jordan. Saudi Med J. 2008;29:1423-1428. [PubMed] [Cited in This Article: ] |
18. | Taleb N, Salti H, Al-Mokaddam M, Merheb M, Salti I, Nasrallah M. Prevalence and determinants of albuminuria in a cohort of diabetic patients in Lebanon. Ann Saudi Med. 2008;28:420-425. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
19. | Lahoz-Rallo B, Blanco-Gonzalez M, Casas-Ciria I, Marín-Andrade JA, Mendez-Segovia JC, Moratalla-Rodriguez G, Quintero-Dominguez R, Ramirez-Raya M, Guerrero-Pinedo MJ, Aguilar-Diosdado M. Cardiovascular disease risk in subjects with type 2 diabetes mellitus in a population in southern Spain. Diabetes Res Clin Pract. 2007;76:436-444. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
20. | del Cañizo Gómez FJ, Moreira Andrés MN. Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus. Med Clin (Barc). 2008;130:641-644. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
21. | Jurado J, Ybarra J, Solanas P, Caula J, Gich I, Pou JM, Romeo JH. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Pract. 2009;21:140-148. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
22. | Harwell TS, Moore K, McDowall JM, Helgerson SD, Gohdes D. Cardiovascular risk factors in Montana American Indians with and without diabetes. Am J Prev Med. 2003;24:265-269. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
23. | Zhang B, Xiang HD, Mao WB, Guo XH, Wang JC, Jia WP, Yu M, Li QF, Fu ZY, Cao WH. Epidemiological survey of chronic vascular complications of type 2 diabetic in-patients in four municipalities. Zhongguo Yixue Kexueyuan Xuebao. 2002;24:452-456. [PubMed] [Cited in This Article: ] |
24. | Meisinger C, Heier M, Landgraf R, Happich M, Wichmann HE, Piehlmeier W. Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study. BMC Health Serv Res. 2008;8:226. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
25. | Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-431. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1062] [Cited by in F6Publishing: 1000] [Article Influence: 50.0] [Reference Citation Analysis (0)] |
26. | Mula-Abed WA, Chilmeran SK. Prevalence of dyslipidemia in the Iraqi adult population. Saudi Med J. 2007;28:1868-1874. [PubMed] [Cited in This Article: ] |